Immunotherapy for Metastatic Renal Cell Carcinoma

Timothy M. Kuzel, MD
Professor of Medicine and Dermatology
Feinberg School of Medicine
Northwestern University
Chicago, Ilinois

ICLIO 1st Annual National Conference
10.2.15
Philadelphia, Pa.

ICLIO | INSTITUTE FOR CLINICAL IMMUNO-ONCOLOGY

AN INSTITUTE OF ACCC
Association of Community Cancer Centers

Financial Disclosures

- I currently have or have the following relevant financial relationships to disclose:
  - Advisory Board: Genentech
  - Consultant: Merck
  - Grant/Research Support: Bristol-Myers Squibb, Genentech, MedImmune, Merck
  - Speakers Bureau: Genentech

Off-Label Use Disclosures

- I **do intend** to discuss off-label uses of products during this activity.

Kidney Cancer is Not a Single Disease



Linehan M, Genome Res 22: 2012

Presented By Cora Sternberg at 2015 ASCO Annual Meeting

Biological Pathways in RCC and Targets of Therapeutic Agents



Rini BI et al. Lancet. 2009;373:1119-1132.

Metastatic RCC: Treatment Results Prior to the Targeted Therapy Era

Therapy	Trials (N)	Patients (N)	ORR (%)	Survival Median (Months)
Observation	7	1139	0.3	6
Hormonal	68	754	6-10	6
Chemotherapy	83	4093	5-10	< 9
INF* INF + Nephrectomy	1	123 123		8.1 12.5
INF INF + Nephrectomy	1	42 41	12 20	7 17

*Off label

Yagoda et al. *Semin Oncol* 1993; Amato RJ. *Semin Oncol* 2000; Flanigan, *NEJM* 2001; Mickisch, *Lancet* 2001.

Interleukin-2 : Background

- Discovered in 1976 and described as a protein that stimulates growth of T cells.[1]
- Recombinant (r) IL-2 first cloned in 1983.[1]
- First given to cancer patients in 1983.[2]
- First phase I studies of rIL-2 in malignant disease in 1984.[4]
- Jurkat cell line-derived IL-2 first used to treat cancer patients in 1985.[3]
- Phase II clinical trials began in 1985.[1]
- FDA approval in 1992.



1. Atkins MB, et al. *J Clin Oncol* 1999; 17:2105-2116.
2. Bindon C, et al. *Br J Cancer* 1983; 47:123-133.
3. Lotze MT, et al. *J Immunol* 1985; 134:157-166.
4. Atkins MB, et al. *J Clin Oncol* 1986; 4:1380-1391.

Interleukin-2: Immunologic Background



Abbas AK and Lichtman AH. *Cellular and Molecular*

- **Natural biologic immunomodulatory agent**
- **Autocrine T-cell growth factor**
  - **Produced exclusively by activated T cells**
  - **Predominantly CD-4+ (T-helper) lymphocytes**
- **Immunomodulatory actions:**
  - **Proliferation and activation of T cells**
  - **Immune response amplification**
  - **Enhanced antibody production by B cells**
  - **NK cell expansion and activation**
- **Stimulates T-cell secretion**
  - **Tumor necrosis factor (TNF)**
  - **Other cytokines (ie, IL-4, interferon-gamma)**
- **Stimulates proliferation and activation of:**
  - **All T cells, including cytotoxic T lymphocytes (CTLs) but also Regulatory T cell (Tregs)**
  - **Natural killer and Lymphokine-activated Killer (LAK) cells**

Schedule for HD-Interleukin-2 Therapy

High-dose IL-2 (HD IL-2) has the potential to induce durable complete responses in a small number of patients

- 600,000 IU/kg (0.037 mg/kg) delivered by 15-min bolus i.v. infusion q8h for 14 doses
- 720,000 IU/kg delivered by 15-min bolus i. v. infusion q8h for 12 doses

Typical Proleukin® Treatment Schedule



- Additional courses of treatment are given if there is some shrinkage following the last course.
- Each treatment course should be separated by a rest period of at least 7 weeks from the date of hospital discharge.

Interleukin-2: Treatment Results in Metastatic RCC

Therapy	Trials N	Patients N	ORR (CR), %	Survival Median, Months	Trial Phase
Observation	7	1139	0.3	6	
LD IL-2 + IFN HD IL-2	1	91 95	10 (3) 23 (8)	13 17	III
HD IL-2	7	255	14 (7)	16	II
HD IL-2 LD IL-2	1	156 150	21 (7) 13 (4)	17 18	III
HD IL-2 IV LD IL-2 IV LD IL-2 SC	1	96 92 93	21 (7) 11 (1) 10 (2)	17 17 17	III

Yagoda, *Semin Oncol* 1993; McDermott, *J Clin Oncol* 2005;
Fisher, *Cancer J* 2000; Yang, *J Clin Oncol* 2003

Response in metastatic RCC to High Dose Interleukin-2

- 15% response rate (7% CR, 8% PR).[1]
- Median duration of response was 54 months for all responders, 20 months for partial responders, and has not yet been reached for complete responders.[1]
- 38% of responders began therapy with tumor burdens > 50 cm^2 on pretreatment scans.
- 60% of partial responders had > 90% regression of all measurable disease.[1]
- 60% of complete responders remain in remission after 30 months.
- Residual disease from some partial responders could be resected.
  - Patients remain alive and disease-free at a minimum of 65+ months



Response Duration for Patients receiving HD IL-2[2]

1. McDermott, *Med Oncol* 2009; 26:S13-S17; 2. Atkins *Kidney Int* 2005; 67:2069-2083

Renal Cell Cancer
Northwestern Experience with Various Regimens



Pamar S,et al. Medical Oncology 22:399, 2005

Response by Baseline Characteristics-Select Study Mcdermott D, et al

Baseline Characteristics	RR (95% CI)	*P* Value*
All Patients (n = 120)	28% (20%-37%)	0.0016
Tumor Type		
Clear Cell (n = 115)	30% (21%-39%)	0.31
Non-Clear Cell (n = 5)	0% (0%-52%)	
MSKCC Risk Group		
Favorable (n = 31)	32% (17%-51%)	0.08
Intermediate (n = 83)	24% (15%-35%)	
Poor (n = 6)	67% (22%-96%)	
UCLA Risk Group		
Low (n = 10)	30% (7%-65%)	0.22
Intermediate (n = 101)	30% (21%-40%)	
High (n = 8)	0% (0%-37%)	

Newer Immunotherapy Approaches in Development

ICLIO | AN INSTITUTE OF ACCC

Anti-PD-1: Blocking T cell Suppression



Keir ME et al, *Annu Rev Immunol* 2008; Pardoll DM, *Nat Rev Cancer* 2012

Phase I Nivolumab Multidose Regimen

- **Eligibility: advanced melanoma, NSCLC, RCC, CRC, or CRPC with PD after 1-5 systemic therapies**



Drake CG, et al. ASCO 2013. Abstract 4514.

Nivolumab: Outcomes in Patients With Metastatic RCC

Dose, mg/kg	Objective Response Rate, % (n/N)	Median DoR, Wks (Range)	SD Rate, % (n/N)	
			≥ 24 Wks	≥ 48 Wks
All doses	29.4 (10/34)	56.1 (36.6-126.7+)	26.5 (9/34)	5.9 (2/34)
1	27.8 (5/18)	56.1 (40.1-76.1+)	22.2 (4/18)	5.6 (1/18)
10	31.3 (5/16)	56.1 (36.6-126.7+)	31.3 (5/16)	6.3 (1/16)

Drake CG, et al. ASCO 2013. Abstract 4514.

Change in Target Lesions From Baseline After Nivolumab Therapy

Patients with mRCC treated with nivolumab 1 or 10 mg/kg



Hodi FS, et al. 12th International Congress on Targeted Anticancer Therapies. Abstract O2.3.

Phase II study design



ClinTrials.gov NCT01354431

[a]Stratified by MSKCC prognostic score (0 vs 1 vs 2/3) and number of prior lines of therapy in the metastatic setting (1 vs >1).

Patient demographics

	Nivolumab, mg/kg			
	0.3 (n=60)	2.0 (n=54)	10 (n=54)	Total (N=168)
MSKCC risk factors, %[a]				
0	33	33	33	33
1	43	41	41	42
2-3	23	26	26	25
Number of metastatic sites, %				
1	22	9	22	18
≥2	78	91	78	82
Prior antiangiogenic regimens, %[a]				
1	57	65	65	62
2	37	30	33	33
3	7	6	2	5

Prior treatment in metastatic setting

	Nivolumab, mg/kg			
	0.3 (n=60)	2.0 (n=54)	10 (n=54)	Total (N=168)
Prior lines of therapy, %				
1	27	30	33	30
2	33	35	43	37
3	40[a]	35	24	33
Common prior agents[b], %				
Sunitinib	77	78	69	74
Everolimus	35	33	33	34
Pazopanib	25	33	24	27
Interleukin-2	25	20	22	23

Objective responses



Best response	%
CR	2
PR	18
Stable	37
PD	40
NE	3

Best response	%
CR	2
PR	20
Stable	43
PD	33
NE	2

Best response	%
CR	0
PR	20
Stable	44
PD	32
NE	4

[a]ORR defined by RECIST v1.1; data cutoff May 15, 2013.
CR, complete response; PR, partial response; PD, progressive disease; NE, not evaluable.

Treatment-related adverse events (≥10% of patients in any arm)

	Nivolumab, mg/kg					
	0.3 (n=59)		2.0 (n=54)		10 (n=54)	
Patients with event, %	Any grade	Grade 3-4	Any grade	Grade 3-4	Any grade	Grade 3-4
Any event	75	5	67	17	78	13
Fatigue	24	0	22	0	35	0
Nausea	10	2	13	2	13	0
Pruritus	10	0	9	2	11	0
Rash	9	0	7	0	13	0
Diarrhea	3	0	11	0	15	0
Appetite decreased	3	0	13	0	4	0
Dry mouth	3	0	6	0	11	0
Dry skin	2	0	6	0	13	0
Hypersensitivity	2	0	2	0	17	0
Arthralgia	2	0	7	0	15	2

Overall survival



	Median OS, months (80% CI)
0.3 mg/kg	18.2 (16.2, 24.0)
2 mg/kg	25.5 (19.8, 28.8)
10 mg/kg	24.7 (15.3, 26.0)

Number of patients at risk

0.3 mg/kg	60	56	50	41	37	35	31	27	24	13	0	0
2 mg/kg	54	52	45	42	38	35	32	28	26	12	0	0
10 mg/kg	54	50	47	45	38	32	29	29	26	8	1	0

Based on data cutoff of March 5, 2014; Symbols represent censored observations.

Overall survival in phase III trials and nivolumab phase II study

	AXIS[1,a]	INTORSECT[2]	RECORD-1[3]	GOLD[4]	Nivolumab study
Drug	Axitinib; sorafenib	Temsirolimus; sorafenib	Everolimus; placebo	Dovitinib; sorafenib	**Nivolumab; 0.3; 2; 10 mg/kg**
Patients, n	389	512	416	570	168
Risk group, %[b]					
Favorable	Not stated	19	29	20	33
Intermediate		69	56	58	42
Poor		12	14	22	25
Prior therapy	Sunitinib	Sunitinib	VEGF	VEGF + mTOR	VEGF ± mTOR
Line of therapy	2nd	2nd	2nd or higher	3rd or higher	2nd to 4th
Median OS, months	15.2; 16.5	12.3; 16.6	14.8; 14.4	11.1; 11.0	**18.2; 25.5; 24.7**
CI	12.8, 18.3[c] 13.7, 19.2[c]	10.1,14.8[c] 13.6, 18.7[c]	Not stated	9.5, 13.4[c] 8.6, 13.5[c]	16.2, 24.0[d] 19.8, 28.8[d] 15.3, 26.0[d]

[a]Post TKI subset; [b]Total ≠100% due to rounding; [c]95% CI; [d]80% CI.

1. Motzer R, et al. *Lancet Oncol.* 2013;14:552-62; 2. Hutson TE, et al. *J Clin Oncol.* 2014;32:760-7; 3. Motzer R, et al. *Cancer.* 2010;116:4256-65;

Phase III Study of Nivolumab vs Everolimus in Pts With mRCC

- **A randomized, open-label phase III trial**



ClinicalTrials.gov NCT01668784.

- **Primary endpoint: OS**
- **Secondary endpoints: PFS, ORR, DoR, OS in PD-L1 subgroup, safety**

Kaplan–Meier Curve for Overall Survival



Motzer RJ et al. N Engl J Med 2015. DOI: 10.1056/NEJMoa1510665

The NEW ENGLAND JOURNAL of MEDICINE

Overall Survival in Subgroup Analyses and Kaplan–Meier Curve for Progression-free Survival.

A Subgroup Analyses of Overall Survival

Subgroup	Nivolumab	Everolimus	Unstratified Hazard Ratio for Death (95% CI)
	no. of events/total no.		
Overall	183/410	215/411	0.76 (0.62–0.92)
MSKCC prognostic score			
Favorable	45/145	52/148	0.89 (0.59–1.32)
Intermediate	101/201	116/203	0.76 (0.58–0.99)
Poor	37/64	47/60	0.47 (0.30–0.73)
Previous antiangiogenic regimens			
1	128/294	158/297	0.71 (0.56–0.90)
2	55/116	57/114	0.89 (0.61–1.29)
Region			
United States or Canada	66/174	87/172	0.66 (0.48–0.91)
Western Europe	78/140	84/141	0.86 (0.63–1.16)
Rest of the world	39/96	44/98	0.78 (0.51–1.20)
Age			
<65 yr	111/257	118/240	0.78 (0.60–1.01)
≥65 to <75 yr	53/119	77/131	0.64 (0.45–0.91)
≥75 yr	19/34	20/40	1.23 (0.66–2.31)
Sex			
Female	48/95	56/107	0.84 (0.57–1.24)
Male	135/315	159/304	0.73 (0.58–0.92)



B Kaplan–Meier Curve for Progression-free Survival



RR favored Nivo
25% vs 5%

Motzer RJ et al. N Engl J Med 2015. DOI: 10.1056/NEJMoa1510665

The NEW ENGLAND JOURNAL of MEDICINE

Correlation of PD-L1 expression in pre-treatment tumor biopsies with clinical outcomes

PD-L1 expression by IHC in 61 pretreatment tumor biopsies across tumor types from 42 patients[a]





Patient samples: 18 MEL, 10 NSCLC, 7 CRC, 5 RCC, 2 CRPC

[a]Analysis was not pre-planned and based on a subset of patients
[b]2 patients still under evaluation

Topalian et al NEJM, 2012

RCC Immunotherapy Trial

Figure 1. Study design



[a]For expansion cohorts NIVO3 + IPI1 and NIVO1 + IPI3 and for NIVO3 + IPI3, one prior adjuvant or neoadjuvant therapy for localized or locally advanced RCC is allowed provided recurrence occurred ≥6 months after the last dose of the adjuvant or neoadjuvant therapy. Interferon alpha or interleukin-2 (IL-2) as prior therapy is allowed

AE = adverse event; DOR = duration of response; IPI1 = ipilimumab 1 mg/kg; IPI3 = ipilimumab 3 mg/kg; IV = intravenous; NIVO1 = nivolumab 1 mg/kg; NIVO3 = nivolumab 3 mg/kg; ORR = objective response rate; PFS = progression-free survival; Q2W = every 2 weeks; Q3W = every 3 weeks; RECIST = Response Evaluation Criteria in Solid Tumors

- At induction visits, patients received two infusions. The first infusion was always nivolumab (1 or 3 mg/kg), and the second was always ipilimumab, which was started ≥30 minutes after completion of the nivolumab infusion (Figure 2)

Ipilimumab/Nivolumab in RCC Efficacy

Efficacy

- ORR and best overall response are shown in Table 6

Table 6. Antitumor activity

	NIVO3 + IPI1	NIVO1 + IPI3	NIVO3 + IPI3
	N = 47	N = 47	N = 6
Confirmed ORR[a], n (%) 95% CI	18 (38.3) 24.5–53.6	19 (40.4) 26.4–55.7	0
Best overall response[b], n (%)			
Complete response	4 (8.5)	1 (2.1)	0
Partial response	14 (29.8)	18 (38.3)	0
Stable disease	17 (36.2)	17 (36.2)	5 (83.3)
Progressive disease	10 (21.3)	7 (14.9)	1 (16.7)

[a]Confirmed response only; [b]No unconfirmed complete responses were reported in either arm; unconfirmed partial responses were reported in one patient (2.1%) in the NIVO3 + IPI1 arm and in two patients (4.3%) in the NIVO1 + IPI3 arm. Best overall response was not determinable in one patient (2.1%) in the NIVO3 + IPI1 arm and in two patients (4.3%) in the NIVO1 + IPI3 arm

- The median DOR is shown in Figure 3
- Of those who responded to treatment, 72.2% (13/18) of patients in the nivolumab 3 + ipilimumab 1 arm and 63.2% (12/19) of patients in the nivolumab 1 + ipilimumab 3 arm had ongoing responses
- Median DOR was 67.7 weeks (range 4.1+ to 91.1+) in the nivolumab 3 + ipilimumab 1 arm and 81.1 weeks (range 6.1+ to 81.1+) in the nivolumab 1 + ipilimumab 3 arm
  - DOR was defined as the time between date of first response and date of disease progression or death (whichever occurred first)

Duration of Responses



- The PFS rate (95% CI) at 24 weeks was 54% (39–68) in the nivolumab 3 + ipilimumab 1 arm (N = 47) and 68% (52–79) in the nivolumab 1 + ipilimumab 3 arm (N = 47) (Figure 4)

Toxicity of Ipi/Nivo Rx in RCC

Table 5. Treatment-related select AEs[a,b]

Category, n (%)	NIVO3 + IPI1 N = 47		NIVO1 + IPI3 N = 47		NIVO3 + IPI3 N = 6	
	Any grade	Grade 3/4	Any grade	Grade 3/4	Any grade	Grade 3/4
Skin disorder	18 (38.3)	0	24 (51.1)	1 (2.1)	3 (50.0)	0
GI disorder	11 (23.4)	1 (2.1)	21 (44.7)	11 (23.4)	3 (50.0)	2 (33.3)
Endocrinopathy	11 (23.4)	1 (2.1)	20 (42.6)	0	5 (83.3)	0
Hepatic	7 (14.9)	2 (4.3)	15 (31.9)	10 (21.3)	3 (50.0)	0
Renal disorder	5 (10.6)	1 (2.1)	7 (14.9)	1 (2.1)	2 (33.3)	0
Infusion reaction	4 (8.5)	0	3 (6.4)	0	1 (16.7)	0
Pulmonary	2 (4.3)	0	3 (6.4)	0	0	0

[a]Select AEs were defined as AEs with potential immune-mediated etiology that may require special monitoring and specific unique interventions
[b]Treatment-related select AEs are ordered by decreasing frequency in the NIVO3 + IPI1 arm

Conclusions of Immunotherapy Approaches to mRCC

- **High Dose Interleukin-2 offers for pts with clear cell mRCC high objective response rates and opportunities for durable remissions**
- **Single agent anti PD-1 therapy shows activity in relapsed setting with improved median OS compared to historical controls- randomized trial completed and reported positive in press release**
- **Combination CTLA-4 inhibition and anti PD-1 inhibition associated with impressive response rates, with significant 60% ongoing responses**
- **Toxicity appears consistent with prior reports of these combinations**
- **Phase III trial of combination vs sunitinib underway**

Audience Questions

ICLIO | INSTITUTE FOR CLINICAL IMMUNO-ONCOLOGY

AN INSTITUTE OF ACCC
Association of Community Cancer Centers